Verona Pharma plc (NASDAQ:VRNA) finished Friday with a subtraction of -$0.46 to close at $18.51, a downside of -2.42 percent. An average of 459,400 shares of common stock have been traded in the last five days. There was a fall of -$1.42 in the past week, and it reached a new high 9 times over the past 12 months. The last 20 days have seen an average of 333,440 shares traded, while the 50-day average volume stands at 371,818.
VRNA stock has decreased by -14.82% in the last month. The company shares reached their 1-month lowest point of $17.44 on 08/09/23. With the stock rallying to its 52-week high on 01/03/23, shares of the company touched a low of $8.41 and a high of $26.44 in 52 weeks. It has reached a new high 1 time so far this year and lost -29.16% or -$7.62 in price. In spite of this, the price is down -29.99% from the 52-week high.
Insider Transactions
VRNA stock investors should be aware that Verona Pharma plc (VRNA) stock had its last reported insider trading activity 5 days ago on Aug 07. In this transaction, the insider spent $21,263. Chief Financial Officer, Hahn Mark W, disposed of 8,616 shares at a price of $2.47 on Aug 07. The insider now owns more than $21,263 worth of shares. Prior to that, Chief Medical Officer Rickard Kathleen A. went on to Sale 1,600 shares at $2.47 each on Aug 07. An amount of $3,949 was transacted.
Valuation Metrics
Verona Pharma plc (VRNA) stock’s beta is 0.22. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2957.53, the price-to-book (PB) ratio at 5.28.
Financial Health
The quick ratio of Verona Pharma plc for the three months ended June 29 was 26.30, and the current ratio was 26.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.07 and a total debt to equity ratio of 0.07 for the quarter ending June 29. Verona Pharma plc’s EBITDA margin for the year ending June 29 is -16400.44%. Its gross profit as reported stood at $0.11 million compared to revenue of $0.46 million.
Earnings Surprise
For the three-month period that ended June 29, Verona Pharma plc had $19.86 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$8.81 million in the quarter, while revenues of -$16.74 million were shrunk -101.7%. The analyst consensus anticipated Verona Pharma plc’s latest quarter earnings to come in at -$0.29 per share, but it turned out to be -$0.08, a 72.40% surprise. For the quarter, EBITDA amounted to -$9.81 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Verona Pharma plc (VRNA) price momentum. RSI 9-day as of the close on 11 August was 33.86%, suggesting the stock is Neutral, with historical volatility in this time frame at 34.54%.
As of today, VRNA’s price is $18.71 -7.12% or -$1.42 from its 5-day moving average. VRNA is currently trading -16.21% lower than its 20-day SMA and -2.94% lower than its 100-day SMA. However, the stock’s current price level is -13.99% below the SMA50 and +80.41% above the SMA200.
The stochastic %K and %D were 26.69% and 19.12%, respectively, and the average true range (ATR) was 1.04. With the 14-day stochastic at 21.75% and the average true range at 1.03, the RSI (14) stands at 37.20%. The stock has reached -0.76 on the 9-day MACD Oscillator while the 14-day reading was at -1.22.
